There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this
NICE has recommended NHS funding for Roche’s Rozlytrek (entrectinib) as a treatment option for advanced non-small cell lung cancer with a rare mutation in final draft guidance.
Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the
NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft